Gilead Sciences, an American biopharmaceutical company, to invest $35m in HOOKIPA Pharma, a clinical-stage biopharmaceutical company. "Gilead is helping to advance our novel arenaviral platform technology, which has the potential to complement Gilead’s overall research strategies for cures of HIV and HBV," Joern Aldag, HOOKIPA CEO.